# Evidence for a New Graves Disease Susceptibility Locus at Chromosome 18q21

Bijayeswar Vaidya,<sup>1</sup> Helen Imrie,<sup>1</sup> Petros Perros,<sup>2</sup> Eric T. Young,<sup>3</sup> William F. Kelly,<sup>4</sup> David Carr,<sup>5</sup> David M. Large,<sup>6</sup> Anthony D. Toft,<sup>7</sup> Pat Kendall-Taylor,<sup>1</sup> and Simon H. S. Pearce<sup>1</sup>

<sup>1</sup>Department of Endocrinology, School of Clinical Medical Sciences, University of Newcastle upon Tyne, and <sup>2</sup>Department of Medicine, Freeman Hospital, Newcastle upon Tyne, UK; <sup>3</sup>Department of Medicine, Wansbeck General Hospital, Ashington, Northumbria, UK; <sup>4</sup>Diabetes Care Centre, Middlesbrough General Hospital, Middlesbrough, UK; <sup>5</sup>Department of Medicine, North Tees General Hospital, Stockton on Tees, UK; <sup>6</sup>Department of Medicine, Cumberland Infirmary, Carlisle, UK; and <sup>7</sup>Endocrine Unit, Royal Infirmary of Edinburgh, Edinburgh

Graves disease (GD) is a common autoimmune thyroid disorder that is inherited as a complex multigenic trait. By using a single microsatellite marker at each locus, we screened the type 1 diabetes loci *IDDM4*, *IDDM5*, *IDDM6*, *IDDM8*, and *IDDM10* and the fucosyltransferase-2 locus for linkage in sib pairs with GD. This showed a two-point nonparametric linkage (NPL) score of 1.57 (P = .06) at the *IDDM6* marker *D18S41*, but NPL scores were <1.0 at the other five loci. Thus, the investigation of the *IDDM6* locus was extended by genotyping 11 microsatellite markers spanning 48 cM across chromosome 18q12-q22 in 81 sib pairs affected with autoimmune thyroid disease (AITD). Multipoint analysis, designating all AITD sib pairs as affected (74 sib pairs) showed a peak NPL score of 3.09 (P = .001). Linkage to this region has been demonstrated in type 1 diabetes (*IDDM6*), rheumatoid arthritis, and systemic lupus erythematosus, which suggests that this locus may have a role in several forms of autoimmunity.

Graves disease (GD) (MIM 275000) is a common organspecific autoimmune disorder, in which hyperthyroidism occurs because of the stimulation of the thyrotropin receptor by a thyroid-stimulating autoantibody. There is a strong genetic component in the pathogenesis of GD, with an estimated  $\lambda_s$  of 10–15 (Brix et al. 1998). Recent linkage and family-based association studies of GD have identified several susceptibility loci at different chromosomal regions—including 6p21 (major histocompatibility complex [*MHC*]) (Heward et al. 1998; Vaidya et al. 1999), 2q33 (cytotoxic T lymphocyte antigen-4 [*CTLA-4*]) (Heward et al. 1999; Vaidya et al. 1999), 14q31 (*GD-1*) (Tomer et al. 1998*a*), 20q13 (*GD-2*) (Tomer et al. 1998*b*; Pearce et al. 1999), and Xq21 (*GD-*3) (Barbesino et al. 1998)—providing evidence that GD, like most autoimmune diseases, is inherited as a complex multigenic trait.

An excess concurrence of GD and type 1 diabetes (IDDM) in the same patients or their relatives suggests that IDDM and GD could share some susceptibility alleles (Payami et al. 1989). Indeed, recent studies have demonstrated that the MHC and CTLA-4 loci are linked to both IDDM and GD (Davies et al. 1994; Nisticò et al. 1996; Marron et al. 1997; Heward et al. 1998, 1999; Vaidya et al. 1999). Genomewide linkage scans for IDDM have revealed many different chromosomal regions of linkage, and several of these loci have been replicated in further data sets (Davies et al. 1994; Hashimoto et al. 1994; Concannon et al. 1998; Mein et al. 1998). Replication of such a result in a different but pathogenically allied disorder would provide independent confirmation of the linkage. Thus, we screened the following putative IDDM loci in multiplex GD families for linkage: IDDM4 (11q13), IDDM5 (6q25), IDDM6 (18q21), IDDM8 (6q27), and IDDM10 (10p11-q11) (Davies et al. 1994, 1996; Hashimoto et al. 1994; Luo et al. 1996; Delepine et al. 1997; Merriman et al. 1997, 1998; Reed et al. 1997; Concannon et al. 1998; Mein

Received December 20, 1999; accepted for publication February 18, 2000; electronically published April 3, 2000.

Address for correspondence and reprints: Dr. B. Vaidya, Dept. of Medicine, 4th Floor Leech Building, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, United Kingdom. E-mail: bvaidya@hgmp.mrc.ac.uk

<sup>@</sup> 2000 by The American Society of Human Genetics. All rights reserved. 0002-9297/2000/6605-0028 & 02.00

Table 1

Phenotypes of Sib Pairs with AITD								
	Sib Pairs with GD Only (GD–GD)	Sib Pairs with GD and AH (GD–AH) <sup>a</sup>	All Sib Pair with AITI					
Full sib pairs Half sib pairs Total	69 5 74 <sup>b</sup>	7 0 7	76 5 81					

<sup>a</sup> Families were selected only if they had at least two sibs with GD. Seven of these families had additional sibs with AH (GD-AH sib pairs).

<sup>b</sup> Seventy-one sib pairs with GD were available at the time of preliminary two-point linkage analysis.

et al. 1998; Nakagawa et al. 1998). Studies have shown that inability to secrete the soluble glycoprotein forms of the ABH blood group antigens (nonsecretor phenotype) is also associated with IDDM and GD (Blackwell et al. 1987; Collier et al. 1988). In whites this trait is due to a common nonsense mutation of the fucosyltransferase-2 (FUT-2) gene (Kelly et al. 1995), located on chromosome 19q13, which suggests that markers close to this locus may also be linked to these disorders. We have, therefore, examined linkage of GD to the marker D19S888, which is within 1 cM of the FUT-2 locus.

Sixty-seven white families with two or more sibs affected with GD (including 152 individuals with GD [26 males], 22 with autoimmune hypothyroidism [AH], and 73 unaffected subjects) were recruited from the north of England and the Lothian region of Scotland (table 1). Parents (n = 49) and unaffected sibs (n = 37) were studied if available. The diagnostic criteria for GD and the

#### Table 2

Two-Point Linkage Analysis at the Various Candidate Loci in Families with GD

Locus	Chromosome	Marker	NPL score	Р	Information Content
IDDM4	11q13	D11S1917	62	.73	.40
IDDM5	6q25	ESR	.91	.18	.64
IDDM6	18q21	D18S41	1.57	.06	.44
IDDM8	6q27	D6S281	.48	.31	.58
IDDM10	10p11-q11	D10S193	-1.05	.85	.61
FUT-2	19q13	D19S888	85	.80	.62

characteristics of these families have been described elsewhere (Vaidya et al. 1999).

We screened the cohort of sib pairs affected with GD (71 sib pairs available at the time of screening) (table 1) for linkage to the single markers at IDDM4, IDDM5, IDDM6, IDDM8, IDDM10, and FUT-2. This showed a two-point nonparametric linkage (NPL) score of 1.57 (P = .06) at the IDDM6 marker D18S41. NPL scores were all <1.0 at the other five loci (table 2). Thus, we extended linkage analysis of the IDDM6 region by genotyping 10 additional microsatellite markers (a total of 11 markers), spanning a 48-cM region of chromosome 18q12-q22. Multipoint linkage analysis in the cohort of 81 sib pairs affected with autoimmune thyroid disease (AITD) (table 1) showed a peak NPL score of 3.46 (P = .0003), at the marker D18S487 (fig. 1). The designation of only subjects with GD as "affected" (74 sib pairs) showed a peak NPL score of 3.09 (P = .001) (fig. 1). The proportion of the 76 full sibs with AITD sharing zero alleles (z0) reached a minimum of 0.137 close to marker D18S487, which suggests that the locus-specific  $\lambda_s$  for this region is 1.8. The 26 families with affected

#### Table 3

Chromosome 18g12-g22 Markers Sibs Unaffected Marker Map Probands Corrected Pb Allele (mu) with GD<sup>a</sup> with GD<sup>a</sup> Р Marker (cM)D18S57 .0 107 9/7 5/11 .143 .429 D18S470 12.0 289 4/4 0/8 .114 .038 Ι Ι

Intrafamilial Association between Probands with GD and Unaffected Sib Controls at

D18S487	18.4	119	14/10	6/18	.020	.020
D18S41	22.7	203	19/11	16/14	.300	
D18S1144	24.8	165	3/5	1/7	.285	
D18S64	28.3	207	6/6	2/10	.096	.288
D18S1134	31.8	213	22/14	16/20	.118	.354
D18S1147	34.9	213	9/9	3/15	.038	.114
bcl-2	37.7	195	13/5	10/8	.244	
D18S465	40.8	239	7/5	1/11	.014	.042
D18S485	47.8	183	13/11	7/17	.071	.213

<sup>a</sup> Number of occurrences/nonoccurrences of candidate alleles (Curtis 1997). Totals of the can-

didate alleles differentially occurring in the probands and in the unaffected siblings were compared. <sup>b</sup> Fisher's exact test, corrected for multiple allelic comparisons. The three most common alleles were tested for association, but not at marker D18S487, where a candidate allele was already known (Merriman 1997).



Figure 1 Multipoint linkage analysis of 11 markers on chromosome 18q12-q23. A, Percent information content over the marker map. B, The NPL score obtained by "scoring all" affected subjects with GD (solid line) and AITD (broken line) with the use of the GENE-HUNTER package (Kruglyak et al. 1996) is shown, against the marker map on the x-axis. The peak NPL score of 3.46 occurs at marker D18S487. The microsatellite markers were genotyped with the use of fluorescently-labeled PCR and resolved on a semiautomated 373 ABI sequencer. The primers were taken from the Genethon genetic linkage map, except for bcl-2 (Mehrian et al. 1998). The marker map was derived from the Genetic Location Database and the Center for Medical Genetics-Marshfield Medical Research Foundation databases. The minimum proportion of full sib pairs sharing zero alleles (z0) was calculated with the use of MAPMAKER/SIBS (Kruglyak and Lander 1995). The population allele frequencies for each marker were derived by genotyping local white controls.

AITD males (brother-sister sib pairs) showed a peak NPL of 2.03 (P = .02, z0 = 0.172,  $\lambda_s = 1.5$ ), compared with 3.20 (P = .0008, z0 = 0.058,  $\lambda_s = 4.3$ ) in the 41 families with only affected females.

To assess potential interactions between the chromosome 18 locus and other putative GD loci in our population, we weighted data from the chromosome 18 markers for allele-sharing status (0 or 1 to model epistasis; 1 or 0 to model heterogeneity) at *D2S117* (*CTLA-*4) and *TNF* $\alpha$  (*MHC*), using the modified GENE-HUNTER-plus version 2, as described (Kong and Cox 1997; Cox et al. 1999). Weighting the chromosome 18 data for allele sharing at *D2S117* under a heterogeneity model showed a peak NPL score of 2.92 (*P* = .002, 32 families), which was similar to the NPL of 3.09 obtained in the whole cohort before weighting. No other evidence of interaction between the chromosome 18 locus and *CTLA-4* or *MHC* loci was found.

Family-based association analysis, with the use of un-

affected sibs as controls (Curtis 1997), showed an excess of the 119 mobility unit (mu) allele of *D18S487* (P =.020) in probands with GD (table 3), which is the same allele found to be associated with IDDM (Merriman et al. 1997; T. Merriman, personal communication). This association of GD with the 119 mu allele of *D18S487* was also observed in a population-based case-control study with 166 unrelated probands with GD and 165 controls (27.3% vs. 17.3% in controls, P = .002).

The present study has identified a susceptibility locus for GD at chromosome 18q21, which is close to the *IDDM6* locus. Using a multiplicative model, we can estimate that with a  $\lambda_s$  value of 1.8, the chromosome 18 locus may confer  $\leq 25\%$  of the total genetic susceptibility to GD in our population (Risch 1987). With both intrafamilial and population-based association analyses, we also found weak evidence for an association of GD with the 119 mu allele of *D18S487*. Our data provide some evidence to support genetic heterogeneity between the chromosome 18 locus and *CTLA-4* in our cohort, which suggests that these susceptibility loci may play complementary roles in conferring susceptibility to GD in different families.

One genomewide linkage scan involving 56 AITD families has not found evidence for linkage to this region of chromosome 18 (Tomer et al. 1999). However, our study and other studies showing linkage of this chromosomal region to other autoimmune diseases, such as IDDM (IDDM6) (Davies et al. 1994; Merriman et al. 1997, 1998), rheumatoid arthritis (Cornelis et al. 1998), and systemic lupus erythematosus (Shai et al. 1999), provides evidence that this region is likely to harbor an important autoimmunity locus. Candidate genes close to the region of association include the immunoglobulin gene transcription factor ITF2 and the MAP kinase MAPK4, with the anti-apoptotic bcl2 gene being located ~10cM from the region of strongest linkage. In addition, our findings further strengthen the hypothesis that common susceptibility loci are involved in different autoimmune disorders.

# Acknowledgments

We are grateful to Kath Brown, Jean Gerrard, and Kim Johnson, for sample collection; Dr. Dorothy Trump, The British Thyroid Foundation (Janis Hickey), and Thyroid Eye Disease (Sally Mitchell), for help recruiting; and Dr. Mark I. Mc-Carthy, for statistical advice. This work was supported by The Wellcome Trust.

# **Electronic-Database Information**

Accession numbers and URLs for data in this article are as follows:

Center for Medical Genetics-Marshfield Medical Research

#### Reports

Foundation, http://www.marshmed.org/genetics/Map \_Markers/ maps/indexmap.html (for marker maps)

- Genethon, http://www.genethon.fr/ genethon\_en.html (for microsatellite marker primers)
- Genetic Location Database, http://cedar.genetics.soton.ac.uk/ public\_html/gmap.html (for marker maps)
- Online Mendelian Inheritance in Man (OMIM), http://www .ncbi.nlm.nih.gov/Omim (for GD [MIM 275000])

# References

- Barbesino G, Tomer Y, Concepcion ES, Davies TF, Greenberg DA (1998) Linkage analysis of candidate genes in autoimmune thyroid disease, II: selected gender-related genes and the X chromosome. J Clin Endocrinol Metab 83:3290–3295
- Blackwell CC, James VS, Weir DM, Gemmill JD, Patrick AW, Collier A, Clarke BF (1987) Secretor state of patients with insulin dependent or non-insulin-dependent diabetes mellitus. BMJ 295:1024–1025
- Brix TH, Kyvik KO, Hegedüs L (1998) What is the evidence of genetic factors in the etiology of Graves' disease? Thyroid 8:727–734
- Collier A, Patrick AW, Toft AD, Blackwell CC, James V, Weir DM (1988) Increased prevalence of non-secretors in patients with Graves' disease: evidence for an infective aetiology? BMJ 296:1162
- Concannon P, Gogolin-Ewens KJ, Hinds DA, Wapelhorst B, Morrison VA, Stirling B, Mitra M, et al (1998) A secondgeneration screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 19:292–296
- Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, et al (1998) New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci 95:10746–10750
- Cox NJ, Frigge M, Nicolae DL, Concannon P, Hanis CL, Bell GI, Kong A (1999) Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet 21:213–215
- Curtis D (1997) Use of siblings as controls in case-control association studies. Ann Hum Genet 61:319–333
- Davies JL, Cucca F, Goy JV, Atta ZA, Merriman ME, Wilson A, Barnett AH, et al (1996) Saturation multipoint linkage mapping of chromosome 6q in type 1 diabetes. Hum Mol Genet 5:1071–1074
- Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, et al (1994) A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371: 130–136
- Delepine M, Pociot F, Habita C, Hashimoto L, Froguel P, Rotter J, Cambon-Thomsen A, et al (1997) Evidence of a non-MHC susceptibility locus in type I diabetes linked to HLA on chromosome 6. Am J Hum Genet 60:174–187
- Hashimoto L, Habita C, Beressi JP, Delepine M, Besse C, Cambon-Thomsen A, Deschamps I, et al (1994) Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. Nature 371:161–164
- Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, et al (1999) The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 84:2398–2401

- Heward JM, Allahabadia A, Daykin J, Carr-Smith J, Daly A, Armitage M, Dodson PM, et al (1998) Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and familybased study. J Clin Endocrinol Metab 83:3394–3397
- Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB (1995) Sequence and expression of a candidate for the human secretor blood group alpha (1,2) fucosyltransferase gene (FUT2): homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem 270:4640–4649
- Kong A, Cox NJ (1997) Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 61:1179–1188
- Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 58:1347–1363
- Kruglyak L, Lander ES (1995) Complete multipoint sib-pair analysis of qualitative and quantitative traits. Am J Hum Genet 57:439–454
- Luo DF, Buzzetti R, Rotter JI, Maclaren NK, Raffel LJ, Nisticò L, Giovannini C, et al (1996) Confirmation of three susceptibility genes to insulin-dependent diabetes mellitus: IDDM4, IDDM5 and IDDM8. Hum Mol Genet 5:693–698
- Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Larrad MTM, Teng WP, et al (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 6: 1275–1282
- Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, Gauderman WJ, et al (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41:596–602
- Mein CA, Esposito L, Dunn MG, Johnson GCL, Timms AE, Goy JV, Smith AN, et al (1998) A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet 19:297–300
- Merriman TR, Eaves IA, Twells RC, Merriman ME, Danoy PA, Muxworthy CE, Hunter KM, et al (1998) Transmission of haplotypes of microsatellite markers rather than single marker alleles in the mapping of a putative type 1 diabetes susceptibility gene (IDDM6). Hum Mol Genet 7:517–524
- Merriman T, Twells R, Merriman M, Eaves I, Cox R, Cucca F, McKinney P, et al (1997) Evidence by allelic associationdependent methods for a type 1 diabetes polygene (IDDM6) on chromosome 18q21. Hum Mol Genet 6:1003–1010
- Nakagawa Y, Kawaguchi Y, Twells RC, Muxworthy C, Hunter KM, Wilson A, Merriman ME, et al (1998) Fine mapping of the diabetes-susceptibility locus, IDDM4, on chromosome 11q13. Am J Hum Genet 63:547–556
- Nisticò L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MTM, et al (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Hum Mol Genet 5:1075–1080
- Payami H, Joe S, Thomson G (1989) Autoimmune thyroid disease in type 1 diabetic families. Genet Epidemiol 6: 137-141
- Pearce SH, Vaidya B, Imrie H, Perros P, Kelly WF, Toft AD, McCarthy MI, et al (1999) Further evidence for a suscep-

tibility locus on chromosome 20q13.11 in families with dominant transmission of Graves disease. Am J Hum Genet 65:1462–1465

- Reed P, Cucca F, Jenkins S, Merriman M, Wilson A, McKinney P, Bosi E, et al (1997) Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11q11. Hum Mol Genet 6:1011–1016
- Risch N (1987) Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 40:1–14
- Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, Neuwelt CM, et al (1999) Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 8:639–644
- Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF (1998*a*) Linkage analysis of candidate genes in autoimmune thyroid disease, III: detailed analysis of chromo-

some 14 localizes Graves' disease-1 (GD-1) close to multinodular goiter-1 (MNG-1). J Clin Endocrinol Metab 83: 4321-4327

- (1998b) A new Graves disease-susceptibility locus maps to chromosome 20q11.2. International Consortium for the Genetics of Autoimmune Thyroid Disease. Am J Hum Genet 63:1749–1756
- (1999) Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. J Clin Endocrinol Metab 84:4656–4664
- Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, et al (1999) The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet 8: 1195–1199